Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06387472 · ClinicalTrials.gov registry record · NA
DermAI to Evaluate Human Factor of Testing
A NA study of Contact Dermatitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 151
- Enrollment target
- 1
- Study location
NCT06387472 is a NA study of Contact Dermatitis that has completed, run by Mayo Clinic. The registered enrollment target is 151 participants, above the 102-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06387472, a NA study of Contact Dermatitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
Conditions Studied
Interventions
- DEVICE AI algorithm to evaluate photographs of skin test patch regions
- DEVICE Allergen Patch
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2024-05-08 |
| Est. Completion | 2024-12-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06387472
The ClinicalTrials.gov registry entry for NCT06387472 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (48% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which AI algorithm to evaluate photographs of skin test patch regions is the first listed.
NCT06387472 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06387472 about?
NCT06387472 is a clinical study titled "DermAI to Evaluate Human Factor of Testing". The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
What is the current status of trial NCT06387472?
This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2024-05-08. Estimated completion is 2024-12-13.
What conditions does trial NCT06387472 study?
This clinical trial studies the following conditions: Contact Dermatitis.
What interventions are being tested in trial NCT06387472?
The interventions under investigation include: AI algorithm to evaluate photographs of skin test patch regions (DEVICE), Allergen Patch (DEVICE).
Who is sponsoring clinical trial NCT06387472?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06387472 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.